Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

OncoAlert and ecancer - ESMO 2021 Day 2

ESMO 2021

17 - 21 Sep 2021

Published: 18 Sep 2021

Views: 821

Rating:

Save

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

Dr Gil Morgan from OncoAlert gives his insights on what to look out for from Day 2 of ESMO 2021.

Dr morgan mentions results from trials including VESPER, GIM4 and CheckMate 743.

He also reports that the results from the OncoAlert poster on attitudes towards the use of SBRT in oligometastatic breast cancer are out.

You can watch Dr Morgan's previous roundup here

Follow Dr Morgan on twitter: @OncoAlert

Follow ecancer on twitter: @ecancer

Search and follow #OncoAlertTopTweet to stay up to date.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC

Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA

Adagrasib shows durable clinical benefit in advanced KRAS-mutant NSCLC ( Dr Shirish Gadgeel - Henry Ford Cancer Institute, Detroit, USA )

OncoAlert Round Up for September 15-21, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 15-21, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert Round Up for September 8-14, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for September 8-14, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert Round Up for August 25th - 31st, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert Round Up for August 25th - 31st, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

OncoAlert round up July 28th to August 3rd, 2023

Dr Gil Morgan - Executive Director, OncoAlert

OncoAlert round up July 28th to August 3rd, 2023 ( Dr Gil Morgan - Executive Director, OncoAlert )

Four chemo cycles given with durvalumab and tremelimumab optimise response and...

Dr Niels Reinmuth - University of Muenster, Gauting, Germany

Four chemo cycles given with durvalumab and tremelimumab optimise response and tumour shrinkage in patients with mNSCLC ( Dr Niels Reinmuth - University of Muenster, Gauting, Germany )

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced...

Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer ( Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA )

More from ecancer